AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03783507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order 1
Description: Meal Order 1:~Meal Session 1 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 2 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 3 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 4 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED)
Study NCT03783507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order 2
Description: Meal Order 2:~Meal Session 1 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 2 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 3 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 4 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED)
Study NCT03783507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order 3
Description: Meal Order 3:~Meal Session 1 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 2 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 3 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 4 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED)
Study NCT03783507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order 4
Description: Meal Order 4:~Meal Session 1 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 2 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 3 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 4 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED)
Study NCT01912066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stillen
Study NCT01912066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytotec (reference drug)
Study NCT01912066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID (Aceclofenac)
Study NCT01912066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID (Aceclofenac)
Study NCT00621374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)
Description: There is also the possibility that the two treatments together may be even more helpful than either one alone. Because some of the patients in this study will get both CBT and self-hypnosis, we will be able to determine if each one facilitates the efficacy of the other. If the patients treated in this study report benefits, as we expect they will, then this will encourage us to design and complete a larger study to better understand how patients with MS would benefit from these treatments.
Study NCT00621374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: One treatment module is we will study is called cognitive restructuring or cognitive-behavior therapy (CBT). In this treatment, people learn to identify negative thoughts that make them feel bad or anxious. Such negative thoughts lead to feelings of frustration and anxiety, and can even increase the experience of pain, because they cause a person to focus more on pain. With CBT, people learn to identify and stop these thoughts, and then replace them with more reassuring ones. When they do this, they feel more relaxed and focus less on their pain. As a result, they often say that they feel much better and are less aware of pain.
Study NCT00621374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Hypnosis Training (HYP)
Description: Self-hypnosis (HYP) is another strategy that people can learn to manage pain. With this treatment, people learn to enter a state of focused attention, and then change how they experience pain. Although we do not yet know how hypnosis works, research has repeatedly shown that the effects are real; when people report decreases in pain with hypnosis, scans and images of the brain's activity show decreases in the parts of the brain that process pain information. With hypnosis, people are not just pretending to feel less pain, they actually do feel less pain.
Study NCT00621374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Control (CONT)
Description: The CONT condition for this study will include lectures that are interactive and are compelling and informative enough to be both (1) credible as an attentional control condition and (2) perceived as helpful to subjects. The CONT condition will not, however, include instructions in making specific cognitive or behavioral changes related to pain management. Thus, it could control for non-specific factors related to behavioral treatment, but will not impact the primary outcome measure (pain).
Study NCT02611180 — intervention group
Intervention type: PROCEDURE
Intervention: Skin punch biopsy
Study NCT02611180 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral blood draw
Study NCT00807118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 2 x 4 mg tab in formulation F under fed condition
Study NCT00807118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 1 x 8 mg tab in formulation F under fed condition
Study NCT00807118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
Study NCT00807118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 2 x 4 mg tab in formulation F under fasted condition
Study NCT00807118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Single dose of 1 x 8 mg tab in formulation F under fasted condition
Study NCT04970745 — intervention group
Intervention type: OTHER
Intervention: Transcranial parenchymal color Doppler ultrasound (TCS)
Description: tracing the nigrostriatal echogenic area
Study NCT04970745 — intervention group
Intervention type: OTHER
Intervention: Electromyography (EMG) tremor analysis
Description: observed 1, frequency 2, amplitude (amplitude) 3, correlation between the two sides 4, load and post-drug test differences
Study NCT04133051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Analgesia Using Bupivacaine 0.25%
Description: With Patients placed in sitting position, puncture site will be identified at (T8-9, T9-10, or T10-11) intervertebral spaces. Using aseptic conditions, an 18G Tuohy epidural needle will be used to insert epidural catheter as appropriate.~Induction of epidural analgesia with 10-15 ml bupivacaine 0.25% preoperatively with top up doses of 5-7 ml bupivacaine 0.25% or equivalent administered judiciously till we achieve analgesic level of T4 to L1. The calculated top up doses will be administered each hour using bupivacaine 0.25% or by using a continuous infusion syringe pump for equivalent doses
Study NCT04157374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation training
Description: They have to watch a video showing a person carrying out exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional). then they have to practice them. The observation of the exercises and their performance last 8 minutes (4 minutes for observation and 4 minutes for practice). They have to repeat the exercises 5 times per week for 3 weeks.
Study NCT04157374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Exercises
Description: Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.
Study NCT04157374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Exercises
Description: Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.
Study NCT01702844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
Study NCT02193776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: oral
Study NCT02193776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bedaquiline
Description: oral
Study NCT02193776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral
Study NCT02193776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: oral
Study NCT02193776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet
Description: oral
Study NCT04346095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Sedatives with or Without Analgesia
Description: The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
Study NCT04346095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Sedatives with or Without Analgesia
Description: The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
Study NCT01311817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)
Description: 1mL liquid contained in an adhesive skin patch
Study NCT01311817 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)
Description: 1mL liquid contained in an adhesive skin patch
Study NCT00555412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A - 10 mg loxapine q 4 h x 3 (30 mg total)
Description: loxapine aerosol inhalation high dose regimen (30 mg total)
Study NCT00555412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)
Description: loxapine aerosol inhalation middle dose regimen (20 mg total)
Study NCT00555412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C - 5 mg loxapine q 4 h x 3 (15 mg total)
Description: loxapine aerosol inhalation low dose regimen (15 mg total)
Study NCT00555412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D - inhaled placebo q 4 h x 3
Description: placebo aerosol inhalation (0 mg total)
Study NCT01269112 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: citrate regional anticoagulation
Description: Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation
Study NCT01269112 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: citrate regional anticoagulation
Description: Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation
Study NCT00721006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MESENDO
Description: 40 subcutaneous injections of biological product
Study NCT00721006 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 subcutaneous injections of placebo
Study NCT04834570 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of life in Breast Cancer Survivors
Description: The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ - BR-23~* FACT-B
Study NCT01077635 — intervention group
Intervention type: DRUG
Intervention: Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
Description: HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
Study NCT01139502 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Work rehabilitation based on the cognitive therapeutical model
Description: Work rehabilitation including two weekly meetings in which participant and work consultant discuss problems interfering with work and social interaction. Home work related to these problems is assigned between the meetings.
Study NCT01139502 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Work rehabilitation with the addition of cognitive training
Description: Work rehabilitation with the addition of two hours weekly training of concentration, memory, and executive function
Study NCT03675503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Prevention Decision Support
Description: Decision support used by nurses to appropriately provide ambulatory aids to hospitalized patients in order to reduce hospital falls
Study NCT01295385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NUCLEAR MAGNETIC RESONANCE IMAGING
Description: Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers.
Study NCT01295385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NUCLEAR MAGNETIC RESONANCE IMAGING
Description: Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique and to estimate the metabolic and structural abnormalities in this population.
Study NCT04392739 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tpoxx
Description: oral antiviral
Study NCT02159586 — intervention group
Intervention type: DEVICE
Intervention: gastric electrical stimulator
Study NCT03650621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic acupuncture
Description: 5 magnetic acupuncture stickers will be placed on the infants ear
Study NCT03650621 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: stickers (magnets removed)
Description: in this group 5 stickers (magnets removed) will be placed on the infants ear
Study NCT04125563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsicum Oleoresin
Description: The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin (8-methyl-N-vanillyl-6-nonenamide) (from chili extract).
Study NCT04125563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Soft gel capsules filled with placebo - sorbitol and colorant.
Study NCT04078802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VNOTES/VH
Description: same as above
Study NCT01884077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Shoulder Arthroplasty
Description: REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
Study NCT01884077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Shoulder Arthroplasty
Description: TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
Study NCT01706458 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sipuleucel-T
Description: Given IV
Study NCT01706458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Given IV
Study NCT01706458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: Given ID
Study NCT03820609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intervention
Description: This digital application for sexual assault prevention can be completed on a tablet computer.
Study NCT02760940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral liposomal iron
Description: After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
Study NCT06579430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green near infrared fluorescence imaging
Description: ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 2.5 mg/mL as recommended by the manufacturer (Verdye). 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patient\&amp;#39;s height and weight.
Study NCT06579430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green near infrared fluorescence imaging
Description: ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 0.5 or 2.5 mg/mL as recommended by the manufacturer. 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patients height and weight. Different administration rates (fast: 2s, slow: 15-20s) and a different camera system were tested.~Group 1: Quest Platform 2.0; Fast/Slow; 2.5 mg/mL Group 2: Quest Platform 2.0; Slow/Fast; 2.5 mg/mL Group 3: Quest Platform 2.0; Fast/Fast; 2.5 mg/mL Group 4: Stryker Spy-Elite; Fast/Fast; 2.5 mg/mL Group 5: Quest Platform 2.0; Fast/Fast; 0.5 mg/mL
Study NCT00793858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo, isotonic ciclesonide, hypotonic ciclesonide
Description: 200mcg/nostril
Study NCT00793858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, isotonic ciclesonide, hypotonic ciclesonide
Description: 200mcg/nostril
Study NCT03166514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially Available Food Bar
Study NCT03166514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03326596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1000 mg/10ml normal saline infusion
Description: Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
Study NCT02201524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
Study NCT02201524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 400 mg PF 04965842 daily for 4 weeks
Study NCT02201524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 200 mg PF 04965842 daily for 4 weeks
Study NCT02201524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo for 4 weeks
Study NCT03446235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise instruction with motivational interview
Description: An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. In addition to the basic instruction of exercise and nutrition, an exercise physiologist provides individualized exercise instruction with a motivational interviewing skill, which is a different style from traditional persuasive style of communication between the healthcare professionals and patients.
Study NCT03446235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. Basic instruction about exercise and nutrition is provided at the initial visit.
Study NCT03324607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperpolarized 129Xe gas MRI
Description: There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
Study NCT03324607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevespi Aerosphere
Description: There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
Study NCT00973726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose test
Description: Subjects ingest an oral glucose tolerance test.